Q32 Bio Inc. (NASDAQ: QTTB) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $54.00 price target on the stock.
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform [Yahoo! Finance]